SCHEMBL343448

SCHEMBL343448

COCOc1cc(I)ccc1C(=O)OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47
ABL1 P00519 2/20 0.44
CHEK1 O14757 1/20 0.44
AURKA O14965 1/20 0.44
DAPK3 O43293 1/20 0.44
JAK2 O60674 1/20 0.44
NTRK1 P04629 1/20 0.44
FYN P06241 1/20 0.44
CSF1R P07333 1/20 0.44
RET P07949 1/20 0.44
IGF1R P08069 1/20 0.44
MET P08581 1/20 0.44
PDGFRB P09619 1/20 0.44
PIM1 P11309 1/20 0.44
FGFR1 P11362 1/20 0.44
PRKACA P17612 1/20 0.44
LTK P29376 1/20 0.44
GRK5 P34947 1/20 0.44
KDR P35968 1/20 0.44
MAP2K2 P36507 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257677 0.86 TDP1 (0.46) TDP1FFAR4CA12CA1CA2
SCHEMBL344393 0.86 ALDH1A1 (0.42) EGFRMAPTKDM4EALDH1A1HPGD
SCHEMBL256739 0.86 TDP1 (0.62) TDP1FFAR4CA12CA1CA2
SCHEMBL4145981 0.84 TDP1 (0.49) TDP1ABL1CHEK1AURKADAPK3
SCHEMBL10047544 0.83 TDP1 (0.49) TDP1MAPTKDM4EALDH1A1GAA
SCHEMBL3743259 0.83 TDP1 (0.49) TDP1FFAR4CA12CA1CA2
SCHEMBL4304248 0.83 MAPT (0.51) TDP1ALKMAPTKDM4EALDH1A1
SCHEMBL9125892 0.83 HTT (0.53) TDP1ABL1CHEK1AURKADAPK3
SCHEMBL15849811 0.82 CA12 (0.43) TDP1ABL1CA12CA1CA2
SCHEMBL1402749 0.82 KDM4E (0.49) CHEK1CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025053850-A1 COVALENT KRAS-BINDING COMPOUNDS FOR MEDICAL TREATMENT HYKU BIOSCIENCES INC. (US) 2025-03-13 WO disclosed
US-9643969-B2 (aza)indolizine derivative and pharmaceutical use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2017-05-09 US disclosed
CN-104592224-B (azepine) Indoli zine derivatives and medicinal usage thereof 橘生药品工业株式会社 2016-08-03 CN disclosed
US-9115144-B2 Fused heterocyclic derivative and pharmaceutical use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2015-08-25 US disclosed
CN-103221412-B (aza) indolizine derivatives and their pharmaceutical use Kissei Pharmaceutical Co.,Ltd. (JP) 2015-08-19 CN disclosed
EP-2623505-B1 (AZA)INDOLIZINE DERIVATIVES AS XANTHINE OXIDASE INHIBITORS KISSEI PHARMACEUTICAL (JP) 2015-07-29 EP disclosed
CN-104592224-A (AZA)INDOLIZINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF KISSEI PHARMACEUTICAL 2015-05-06 CN disclosed
US-9023882-B2 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2015-05-05 US disclosed
US-20140296537-A1 FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL USE THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-10-02 US disclosed
EP-2749562-A1 FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL USE THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2014-07-02 EP disclosed
US-20130217878-A1 (AZA)INDOLIZINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2013-08-22 US disclosed
EP-2623505-A1 (AZA)INDOLIZINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2013-08-07 EP disclosed
EP-2415771-B1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL (JP) 2013-07-31 EP disclosed
CN-103221412-A (aza) indolizine derivatives and their pharmaceutical use KISSEI PHARMACEUTICAL 2013-07-24 CN disclosed
US-20120289506-A1 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-11-15 US disclosed
US-8227500-B2 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-07-24 US disclosed
EP-2415771-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES Kissei Pharmaceutical Co., Ltd. (JP) 2012-02-08 EP disclosed
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-01-19 US disclosed
US-20100227864-A1 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-09-09 US disclosed
EP-2133331-A1 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES Kissei Pharmaceutical Co., Ltd. (JP) 2009-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296537-A1 FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL USE THEREOF XDH, URB2, PON1 TDP1 890/4885ABL1 3742/4885CHEK1 4761/4885
US-20100227864-A1 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES XDH, DAO, CBR1 TDP1 935/4885ABL1 2147/4885CHEK1 4459/4885
US-20130217878-A1 (AZA)INDOLIZINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF XDH, CHRM1, PON1 TDP1 232/4885ABL1 1179/4885CHEK1 4223/4885
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES XDH, INMT, PON1 TDP1 631/4885ABL1 1835/4885CHEK1 4519/4885
US-20120289506-A1 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME XDH, DAO, DDO TDP1 488/4885ABL1 1606/4885CHEK1 4375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.